CardioDynamics Reports 22% Revenue Growth in First Quarter 2008

Fifth Consecutive Quarter of Year Over Year Revenue Growth, Largest in Four
Years

SAN DIEGO, April 10 /PRNewswire-FirstCall/ -- CardioDynamics
(Nasdaq: CDIC), the innovator and leader of Impedance Cardiography (ICG)
technology, today reported financial results for fiscal first quarter 2008.
Financial Highlights of First Quarter 2008 Compared with First Quarter
2007 -- Net sales increased 22% to $5.8 million, up from $4.7 million
-- Record $2.3 million international sales, an increase of 364% from
$0.5 million
-- ICG sensor revenue increased 1% to $1,501,000, representing 26% of net
sales, up from $1,488,000, or 31% of sales
-- Operating loss reduced 38% to $852,000, from $1.4 million
-- Cash, equivalents and short-term investments increased to $7.6 million,
up from $3.8 million

Additional Key Operating Milestones for the First Quarter of 2008
-- ICG device sales increased 93% to 266 units, up from a total of
138 units
-- Installed base of BioZ monitors and modules increased 12% to over
8,000 units
-- Carried nearly $1.0 million of order backlog into the second quarter of
2008
-- Field headcount totaled 70 field associates, up from 66 one year ago
-- Entered into distribution and technology license agreements with
Recorders and Medicare Systems, Ltd. (RMS), one of the largest
manufacturers of medical equipment in India.

First Quarter 2008 Operating Results Discussion
The Company reported a net sales increase of 22% to $5.8 million. Sales
growth was primarily driven by a 364% increase in international sales and a
14% increase in the average unit sales price of BioZ monitors compared with
the first quarter of 2007. The significant growth in international sales
during the quarter was the result of the fulfillment of two large hospital
customer orders including the Instituto de Salud del Estado de Mexico (ISEM),
the hospital network of the state of Mexico within the country of Mexico, and
an undisclosed (at the customer's request) eastern European multi-hospital
purchaser.
ICG device sales of 266 units included 52 ICG Modules, 214 ICG monitors,
62 of which were BioZ Dx systems, 6 BioZ Monitors, and 146 Medis ICG monitors.
Overall gross margin percentage decreased 5% to 69%, largely due to the
non-cash provision of $231,000 of additional reserve for excess, slow moving
or obsolete inventory. The additional reserve is primarily driven by lower
projected sales of our older model BioZ monitors and the continued success of
our BioZ trade-up program.
A 1% reduction in operating expenses was achieved through an 18% decrease
in general and administrative expense and 29% reduction in research and
development spending during the period, partially offset by increased
investment in selling and marketing personnel and programs. The increased
revenue and gross margin coupled with reduced operating expenses resulted in
an operating loss improvement of 38% to $852,000, from $1.4 million in the
same period in 2007. Overall net loss improved by 10%, to $1.5 million, or
($0.03) per diluted share.
CEO Comments and Outlook
"We are very pleased with 22% growth in the first quarter, our best growth
quarter in four years," stated Michael K. Perry, Chief Executive Officer of
CardioDynamics. "We continued to make good progress in reducing the operating
loss, down 38% to $852,000, which includes $242,000 of non-cash charges for
depreciation, amortization and equity compensation. We are off to a good
start in the second quarter having already shipped the sizeable backlog that
resulted from domestic orders booked late in the first quarter. Additionally,
we recently increased our U.S. field sales and clinical staff by six
additional associates and have hired a dedicated recruiter to assist with our
efforts to add talented field personnel. Our sights remain on achieving at
least 15% revenue growth for 2008 and delivering positive operating cash flow
in the fourth quarter."
Perry added, "We are energized to partner with RMS in India through our
previously announced Distribution and Technology License Agreements. RMS has
an extensive presence in the developing healthcare market in India, which we
believe will be instrumental in helping drive continued market adoption of our
proprietary BioZ(R) ICG technology. Additionally, we believe RMS to be a
solid technology partner to potentially utilize for low cost development,
clinical research and manufacturing."
Conference Call Information
Michael K. Perry, Chief Executive Officer, and Steve P. Loomis, Chief
Financial Officer, will host a summary of CardioDynamics' first quarter 2008
results in a conference call today, Thursday April 10, 2008, at 4:30 p.m.
(EDT). To access the conference call, dial 800-346-7359 (Code 7784).
International participants can call 973-528-0008 (Code 7784). A replay of the
call will be available for one month following the call at 800-332-6854
(Code 7784). The international replay number is 973-528-0005 (Code 7784).
The Internet webcast can be accessed through the Investor Relations section of
the Company's website at http://www.cdic.com or at:
http://phx.corporate-ir.net/phoenix.zhtml?p=irol-
eventDetails&c=86923&eventID=1810586 (Please copy and paste link, and remove
extra space after second hyphen.)
About CardioDynamics
CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and
leader of an important medical technology called impedance cardiography (ICG).
The Company develops, manufactures and markets noninvasive ICG diagnostic and
monitoring devices and markets proprietary ICG sensors. The Company's ICG
Systems are being used by physicians around the world to help battle the
number one killer of men and women -- cardiovascular disease. Partners
include GE Healthcare, Philips Medical Systems and Mindray. For additional
information, please refer to the company's Web site at http://www.cdic.com.
Forward-Looking (Safe Harbor) Statement
Except for historical and factual information contained herein, this press
release contains forward-looking statements, such as the success of recruiting
efforts and relationship with RMS, anticipated revenue growth rates and cash
flow projections, the accuracy of which is necessarily subject to
uncertainties and risks including the Company's primary dependence on the BioZ
product line, and various uncertainties characteristic of early stage growth
companies, as well as other risks detailed in the Company's filings with the
SEC, including its 2007 Form 10-K. The Company does not undertake to update
the disclosures contained in this press release.

CardioDynamics International Corporation
In thousands, except per share data (unaudited)

Selected Consolidated Three Months Ended
Operational Results February 29, February 28,
2008 2007

Net sales $ 5,762 $ 4,727
Cost of sales 1,775 1,220
Gross margin 3,987 3,507
Research and development 314 443
Selling and marketing 3,722 3,444
General and administrative 771 945
Amortization of intangible assets 32 55
Loss from operations (852) (1,380)
Other expense, net (166) (207)
Loss before income taxes and
minority interest (1,018) (1,587)
Minority interest in income of
subsidiary (134) (14)
Income tax provision (463) (54)
Income (loss) from discontinued
operations, net of tax 127 (7)
Net loss $(1,488) $(1,662)
Net loss per common share:
Basic and diluted $ (0.03) $ (0.03)
Weighted-average shares used in per
share calculation:
Basic and diluted 49,750 48,831

Selected Consolidated Balance February 29, November 30,
Sheet Data 2008 2007

Cash and cash equivalents $ 7,601 $ 8,362
Accounts receivable, net 3,854 4,475
Inventory, net 1,527 1,670
Total current assets 13,586 15,164
Long-term assets 4,708 4,703
Total assets 18,294 19,867
Total current liabilities 5,091 5,620
Long-term liabilities 4,444 4,318
Total liabilities 9,535 9,938
Minority interest 560 407
Shareholders' equity 8,199 9,522

SOURCE CardioDynamics

Steve P. Loomis, Chief Financial Officer of CardioDynamics, 1-800-778-4825,
Ext. 1015, sloomis@cdic.com